Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mitochondrial Cofactors for Chemotherapy-Induced Hyperbilirubinemia in ALL
NCT03564678Phase 2Terminated
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- May 2018
- Primary completion
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of levocarnitine and Compound Vitamin B in hyperbilirubinemia, sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Number of Participants With a Response at 11 days. Started May 2018; status: terminated.
02
Drugs
levocarnitineCompound Vitamin B
03
Conditions
hyperbilirubinemia
Beyond the preview
Go deeper on NCT03564678.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03564678.